Nevro
Menlo Park
About Nevro
Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $100K – $500K
- Total funding: $555.8M
- Funding stage: M&A
- Last round: Post-IPO Debt (Nov 2023)
- Ticker: nyse:NVRO
- Website: nevro.com
- Phone: 6504333206
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Manufacturing, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/nevro-49614 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.